StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

Equities research analysts at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a report released on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Price Performance

Shares of TRVN opened at $1.25 on Thursday. The company has a 50-day moving average of $1.60 and a two-hundred day moving average of $2.11. The stock has a market cap of $1.08 million, a price-to-earnings ratio of -0.03 and a beta of 1.05. Trevena has a one year low of $1.13 and a one year high of $11.50.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.